First AD

Second AD

Alexander B. Olawaiye, MD, is a professor in the Department of Obstetrics & Reproductive Sciences at the University of Pittsburgh, as well as the director of gynecologic cancer research at Magee-Women’s Hospital of the University of Pittsburgh Medical Center

Dr. Alexander Olawaiye presents results from the Phase 3 ROSELLA trial, in which relacorilant combined with nab-paclitaxel significantly improved progression-free and overall survival versus nab-paclitaxel alone in patients with platinum-resistant ovarian cancer, with a manageable safety profile.

ROSELLA: A phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72)

Rapid Readouts

Rapid Readouts is a video program featuring leading experts who provide in-depth reviews of the most pivotal and practice-changing data that have been unveiled at recent medical oncology conferences. In each video, top oncologists in their specialty present slides and posters from these annual symposiums and meetings, while highlighting the ever-changing landscape of treatment choices for patient management.

Alexander Olawaiye, MD, presents results from the phase 3 ROSELLA trial, in which relacorilant combined with nab-paclitaxel significantly improved progression-free and overall survival vs nab-paclitaxel alone in patients with platinum-resistant ovarian cancer, with a manageable safety profile.

ROSELLA: A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel vs Nab-Paclitaxel Monotherapy in Patients With Platinum-Resistant Ovarian Cancer (GOG-3073, ENGOT-ov72)